Acute Pancreatitis Market Report 2025

The acute pancreatitis market size has grown strongly in recent years. It will grow from $5.96 billion in 2024 to $6.31 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to high incidence rates, alcohol consumption patterns, gallstone prevalence, tobacco smoking habits, increasing obesity rates.

The acute pancreatitis market size is expected to see strong growth in the next few years. It will grow to $8.04 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to aging population trends, awareness and early diagnosis initiatives, genetic predisposition studies, advancements in treatment modalities. Major trends in the forecast period include focus on nutritional support, patient education and awareness programs, implementation of standardized protocols, exploration of regenerative therapies, continuous monitoring and follow-up.

The rise in healthcare expenditure is anticipated to drive the growth of the acute pancreatitis market in the coming years. Healthcare expenditure encompasses all resources, both financial and non-financial, utilized in delivering health services and related activities. Several factors contribute to the increase in healthcare spending, including the prevalence of chronic diseases, broader health insurance coverage, and heightened awareness of mental health issues. Acute pancreatitis can result in severe complications such as necrotizing pancreatitis, organ failure, and infections, which require additional treatments, surgeries, and extended hospital stays, thereby significantly increasing healthcare costs. For example, the Canadian Institute for Health Information, a nonprofit organization based in Canada, projected that total health expenditure will reach $344 billion in 2023, reflecting a modest growth of 2.8% compared to the previous year. Thus, the rising healthcare expenditure is a key factor propelling the growth of the acute pancreatitis market.

The escalating incidence of obesity is poised to fuel the expansion of the acute pancreatitis market in the foreseeable future. Obesity, characterized by an excessive accumulation of body fat that poses health risks, is a known risk factor for acute pancreatitis. Its increasing global prevalence contributes to a higher incidence of this condition, thereby increasing the demand for related therapies. In March 2022, the World Health Organization reported a staggering figure of approximately 1 billion individuals worldwide - comprising 650 million adults, 340 million adolescents, and 39 million children - who were obese, with this number still on the rise. Additionally, WHO projections suggest that by 2.02 trillion adults and children will face health issues due to being overweight or obese. Thus, the mounting incidence of obesity serves as a key driver for the acute pancreatitis market.

The anticipated rise in gastrointestinal disorders is poised to be a driving factor behind the growth of the acute pancreatitis market in the forthcoming years. These disorders encompass a spectrum of medical issues affecting the gastrointestinal (GI) tract responsible for digestion and nutrient absorption. Conditions such as cholelithiasis, inflammatory bowel disease, and pancreatitis fall under this category, with pancreatitis often linked to or exacerbated by digestive system complications. This inflammation of the pancreas can be triggered by various factors, some of which are associated with the GI tract. For example, data from Crohn's and Colitis UK in March 2022 indicated that in the UK, one in 123 individuals suffers from ulcerative colitis, a type of inflammatory bowel disease known as Crohn's disease, totaling approximately 500,000 inflammatory bowel disease cases in the country. Hence, the increasing prevalence of gastrointestinal disorders is a significant driver fueling growth within the acute pancreatitis market.

Leading companies in the acute pancreatitis market are focusing on developing innovative technologies, such as dry chemistry slide technology, to accurately measure pancreatic lipase levels. This diagnostic method employs a coated slide with dry reagents to conduct chemical reactions for analyzing biological samples, allowing for quick and precise testing without the use of liquid reagents. For example, in June 2024, IDEXX Laboratories Inc., a diagnostics and healthcare innovation firm based in the U.S., launched the catalyst pancreatic lipase test for diagnosing pancreatitis in dogs and cats, which leverages dry chemistry slide technology for accurate pancreatic lipase measurement. The test delivers rapid, quantitative results in less than 10 minutes and integrates smoothly with current workflows, improving diagnostic efficiency. This innovation aims to enhance the early diagnosis and treatment of pancreatitis, a serious condition in pets, and will be further supported by upcoming advancements like the Catalyst SmartQC Control to streamline veterinary diagnostics even more.

In March 2023, CalciMedica Inc., a biopharmaceutical company based in the U.S., merged with Graybug Vision for an undisclosed amount. This merger aims to strengthen the development of CalciMedica's lead product candidate, Auxora, which is intended for treating severe inflammatory diseases, particularly acute pancreatitis, by pooling resources and expertise. Graybug Vision Inc. is also a U.S.-based biopharmaceutical firm that specializes in creating innovative therapies for ocular diseases.

Major companies operating in the acute pancreatitis market include CalciMedica Inc., SCM Lifescience Co. Ltd., Samsung Bioepis Co Ltd., Global Neurotech Pharma Corporation, Baxter International Inc., B. Braun Melsungen AG, Medtronic plc, Boston Scientific Corporation, Fresenius Kabi AG, Sun BioPharma Inc., Atox Bio Inc., D-Pharm Ltd., Regeneron Pharmaceuticals Inc., Merck & Co Inc, Olympus Corporation, Pfizer Inc., Ionis Pharmaceuticals Inc., Abbott Laboratories, Dynavax Technologies Corporation, GlaxoSmithKline plc, AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Novartis AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson.

North America was the largest region in the acute pancreatitis market in 2024. The regions covered in the acute pancreatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute pancreatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute pancreatitis is a medical condition characterized by the inflammation and enlargement of the pancreas during a brief period. This condition is commonly caused by either gallstones or excessive alcohol consumption.

The primary causes of acute pancreatitis include gallstones, alcohol consumption, and other factors. Gallstones, which are solidified deposits in the gallbladder, can lead to pain and inflammation of the pancreas when they obstruct the pancreatic duct, resulting in acute pancreatitis. Treatment options for acute pancreatitis typically involve intravenous fluid administration, nutritional support, analgesics, and procedures such as endoscopic retrograde cholangiopancreatography (ERCP). The diagnosis of acute pancreatitis is carried out through imaging tests and laboratory assessments conducted by hospitals, clinics, and other healthcare facilities.

The acute pancreatitis market research report is one of a series of new reports that provides acute pancreatitis market statistics, including acute pancreatitis industry global market size, regional shares, competitors with a acute pancreatitis market share, detailed acute pancreatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the acute pancreatitis industry. This acute pancreatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute pancreatitis market includes revenues earned by entities by providing therapies, medications, and procedures aimed at managing and treating the condition. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.